Two Sigma Advisers’s Inozyme Pharma INZY Stock Holding History

Two Sigma Advisers’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-17,000	Closed	-$68K	–	2490
2025 Q2	$68K	Sell	17,000 -71,400	-81%	-$177K	﹤0.01%	2237
2025 Q1	$80.4K	Buy	88,400 +9,700	+12%	+$13.4K	﹤0.01%	2266
2024 Q4	$218K	Buy	78,700 +54,400	+224%	+$207K	﹤0.01%	2100
2024 Q3	$127K	Sell	24,300 -5,300	-18%	-$27.5K	﹤0.01%	2143
2024 Q2	$132K	Sell	29,600 -11,700	-28%	-$56.7K	﹤0.01%	2289
2024 Q1	$316K	Sell	41,300 -29,400	-42%	-$161K	﹤0.01%	2051
2023 Q4	$301K	Sell	70,700 -25,400	-26%	-$90.2K	﹤0.01%	2096
2023 Q3	$404K	Sell	96,100 -114,900	-54%	-$584K	﹤0.01%	1867
2023 Q2	$1.18M	Buy	+211,000	New	+$1.25M	﹤0.01%	1474

Two Sigma Advisers's INZY Position: Q3 2025 in Review

Two Sigma Advisers sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 17,000 shares — an estimated $68K sold.

Two Sigma Advisers first reported a position in INZY in Q2 2023 and held it in 9 quarters. The position peaked at $1.18M in Q2 2023. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

Two Sigma Advisers reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
Two Sigma Advisers sold 17,000 Inozyme Pharma shares in Q3 2025, an estimated $68K.
Two Sigma Advisers first reported a position in Inozyme Pharma in Q2 2023 and held it in 9 quarters.
Two Sigma Advisers's Inozyme Pharma position peaked at $1.18M in Q2 2023.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Two Sigma Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.